Moderna Q2 results announced – the stock gets a boost
Klavs Valters
3/8/2022
•
0 min read
Share this post
Copy URL
Moderna Inc. (MRNA) reported its Q2 financial results before the opening bell on Wall Street on Wednesday. The American biotechnology company posted results that beat expectations, sending the stock higher at the open. The company reported revenue of $4.749 billion for the quarter vs. $4.097 billion expected.
Earnings per share reported at $5.24 per share vs. $4.58 per share estimate. "Today's earnings represent a strong second quarter performance, with $10.8 billion in revenue for the first half of the year. We continue to have advance purchase agreements for expected delivery in 2022 of around $21 billion of sales. Given our strong financial position and commercial momentum, we are announcing today that the Board of Directors has approved a new share repurchase program for $3 billion," Stéphane Bancel, CEO of the company said in a press release. "Despite the slowing economy and challenges in the biotech industry, Moderna is in a unique position: a platform to drive scale and speed in research of new medicines, a strong balance sheet with $18 billion of cash and an agile, mission-driven team of over 3,400 people and growing.
We will continue to invest and grow as we have never been as optimistic about Moderna's future. Right now, we have four infectious disease vaccines in Phase 3 trials, and later this year, we expect important data from proof-of-concept studies in rare diseases and immuno-oncology. Our teams are actively working to prepare these new product launches to help patients and drive growth.
This is an exciting time for Moderna as we continue to see significant scientific and business momentum," Bancel concluded. Moderna Inc. (MRNA) chart The stock was up by around 14% on Wednesday at $187.11 a share. Here is how the stock has performed in the past year: 1 Month +16.71% 3 Month +20.11% Year-to-date -26.68% 1 Year -55.56% Moderna price targets SVB Leerink $77 Piper Sandler $214 Morgan Stanley $199 Deutsche Bank $155 UBS $221 B of A Securities $180 Moderna is the 180 th largest company in the world with a market cap of $74.57 billion.
You can trade Moderna Inc. (MRNA) and many other stocks from the NYSE, NASDAQ, HKEX and the ASX with GO Markets as a Share CFD. Sources: Moderna Inc., TradingView, MetaTrader 5, Benzinga, CompaniesMarketCap
By
Klavs Valters
Account Manager, GO Markets London.
The information provided is of general nature only and does not take into account your personal objectives, financial situations or needs. Before acting on any information provided, you should consider whether the information is suitable for you and your personal circumstances and if necessary, seek appropriate professional advice. All opinions, conclusions, forecasts or recommendations are reasonably held at the time of compilation but are subject to change without notice. Past performance is not an indication of future performance. Go Markets Pty Ltd, ABN 85 081 864 039, AFSL 254963 is a CFD issuer, and trading carries significant risks and is not suitable for everyone. You do not own or have any interest in the rights to the underlying assets. You should consider the appropriateness by reviewing our TMD, FSG, PDS and other CFD legal documents to ensure you understand the risks before you invest in CFDs.
Tuesday, 12 May 2026, at roughly 7:30 pm AEST, Treasurer Jim Chalmers will stand up in Canberra and deliver the 2026-27 Federal Budget. According to Budget.gov.au, that is when the Budget is officially released, with the Budget papers going live online at the same time.
市場對頂尖製程晶圓及先進封裝(Advanced Packaging)的瘋狂胃納,其增長速度早已遠遠超越了全球供應鏈所能溫和承受的極限。這種極端的供需失衡,正強行逼迫各大 AI 龍頭大廠積極評估「第二供貨源(Second-source)」—— 呢點要稍為校準:這並不代表大廠們正在拋棄台積電,而是他們在實戰中迫切需要多一條通往大規模量產的備用防線。
支撐英特爾未來繼續狂飆的牛市邏輯非常直觀:**全球 AI 算力需求依舊極其瘋狂**,台積電的產能死鎖在短期內根本無法解開,這倒逼跨國科技巨頭必須不計代價尋求具備實質技術公信力的第二代工防線。如果英特爾能成功將目前的秘密測試與意向訂單逐步轉化為實質性的商業產出,全球長線資金將繼續為其晶圓代工戰略瘋狂計價。
最後,不容忽視的是更宏觀的 **AI 資本開支大週期**。一旦 Google、微軟、亞馬遜和 Meta 等超大規模雲端商(Hyperscalers)未來在龐大的基礎設施投入上放緩步伐、或是 AI 商業化變現的投資回報率(ROI)不如預期,成個半導體板塊都將迎來泥沙俱下的結構性大回撤,無論英特爾 Foundry 的製程進展得幾咁完美也無法獨善其身。
綜上所述,主導接下來外匯與股票交叉盤生死的黃金變數包括:輝達會否發出實質生產訂單、18A 工藝的最新良率進展、英特爾代工業務的虧損限度、台積電先進封裝擴產速度,以及北美雲端巨頭們的 AI 資本開支是否依舊強悍。